Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver ...
Viking Therapeutics (VKTX) Presents New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol at EASL
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver ...
United Kingdom
Argentina 
Australia 
Austria 
Brazil 
Canada 
Germany 
Ireland 
Italy 
Malaysia 
Mexico 
New Zealand 
Poland 
South Africa 
United States 
